Cytofast Auto: the first fully automatic universal monolayer
cytology processor is born
Paris, December 4, 2025 – 5:45 pm CET – Hospitex international, the fully owned Italian subsidiary of
Aliko Scientific (Ikonisys SA, Euronext Growth Paris: ALIKO) and leader in the production of cytology
medical devices, announces the start of the design of Cytofast Auto, the first fully automated and—most
importantly—universal LBC (Liquid Based Cytology) processor, a project that opens a new phase not only
for Hospitex, but for the entire global cytology sector.

A long-awaited revolution
LBC cytology is today one of the pillars of oncological diagnostics performed in pathology laboratories
worldwide, yet most processes still remain manual, repetitive, operator-dependent, and increasingly
costly for laboratories. Moreover, the few automatic systems available today operate on only one type of
sample (e.g., Pap Test only), forcing laboratories to purchase multiple machines or maintain entire phases
manually.

In this context, Cytofast Auto represents a real paradigm shift: “full walk-away” automation combined
with true universality, meaning the ability to process any cytological specimen, from any organ.
The new Cytofast Auto will be the first model in the new Hospitex Robotics product family, characterized
by the use of collaborative robotic arms that perform human-like functions with unprecedented precision,
speed, and reliability—an approach that has never before been applied to pathology laboratories.

To ensure maximum design reliability, the new system will be developed in collaboration with Dobot
Robotics, one of the most advanced companies in the world of collaborative robotics, with over 72,000
robots installed globally, a presence in more than 80 countries, and now publicly listed on the Hong
Kong Stock Exchange.
From the integration of Hospitex’s patented technologies with Dobot’s robotics expertise, the most
advanced instrument ever designed for anatomical pathology will be born.

A game changer that will reshape the market
This universality is not just a technical breakthrough—it is the factor that will rewrite market dynamics.
From a financial and business standpoint, the ability to process all cytology segments—gynecological
(Pap test), pulmonary, urinary cytology, thyroid samples, fine needle aspiration (FNA) specimens such as
breast nodules, and various biological fluids—on a single platform will redefine the paradigm for
laboratories and manufacturers.

For laboratories, the investment becomes significantly more advantageous: the ability to automate all
cytology types with a single device, combined with a competitive price point, reduces operational costs
and accelerates the return on investment. In this way, the transition from analog to digital is no longer a
complex, expensive endeavor, but a strategic and sustainable choice.



1/3
These features, combined with a forecast market price 20% lower than competitors, realistically
position Cytofast Auto as the dominant LBC platform over the next 5–10 years.

Francesco Trisolini, CEO of Hospitex International, stated: “Cytofast Auto enables Hospitex to access
not only the Pap test market, but the entire field of clinical cytology, exponentially expanding the
addressable market. Cytofast Auto is therefore much more than a new diagnostic tool: it is the
foundation for a new generation of truly automated cytology laboratories. With this project, Hospitex
does not simply aim to introduce an innovative product, but to redefine the operational paradigm of modern
cytology, guiding the global transition toward more efficient, standardized, and accessible workflows.”

Allen Xue, CEO of Dobot Europe Gmbh, stated: “We are proud to enter in the lifescience market in
partnership with Hospitex, a proven leader in Pathology labs devices manufacturing. We believe that
automation will be the key to increase productivity in healthcare, as well as already happened in many
industries. The integration of Dobot and Hospitex technologies will set a step forward to a wider access
of world wide population to health services.”

Financial Outcome
The global LBC cytology market is expanding rapidly, driven by the rise in cancer screening programs, the
progressive aging of the population, and increased access to healthcare in emerging regions.

The introduction of a universal device, more cost-effective than competitors and capable of replacing
entire segments of manual workflows, represents a strategic lever of extraordinary impact. The industrial
and commercial potential of the project is extremely high, and this first development phase marks a
decisive moment in Hospitex’s growth.

From a financial standpoint, recurring revenues from consumables will ensure long-term customer
loyalty and generate a stable and growing stream of recurring income over time.
With Cytofast Auto, the company aims to establish itself as the new global reference in LBC cytology,
building a competitive advantage that will express its full value in the coming years.

The product presentation is planned for June 2026, with the first deliveries for September 2026.


-----------------------

About ALIKO SCIENTIFIC (Ikonisys SA)

Headquartered in Paris, ALIKO SCIENTIFIC is the parent company of an international ecosystem of businesses dedicated to
advancing oncology diagnostics. Listed on Euronext Growth Paris under the ticker ALIKO, the company coordinates industrial,
financial and research activities through its subsidiaries: Ikonisys Inc. (USA) and Hospitex International (Italy). ALIKO
SCIENTIFIC’s mission is to innovate cancer diagnosis by uniting cutting-edge technologies, resources, and strategic
investments to create a global center of excellence in oncology.

For more information, visit: www.alikoscientific.com

About IKONISYS

Ikonisys is a global leader in automated diagnostics, specializing in fluorescence in situ hybridization (FISH) and circulating
tumor cell (CTC) detection. Leveraging advanced artificial intelligence (AI) and a fully automated microscopy platform,
Ikonisys provides unmatched precision, scalability, and efficiency in cancer diagnostics and treatment monitoring.
Recognized as pioneer in automation for rare cell detection, Ikonisys is at the forefront of personalized medicine,
empowering clinicians to deliver targeted therapies and improve patient outcomes.



2/3
For more information, visit: www.ikonisys.com

About HOSPITEX

Hospitex, based in Florence, Italy, is a global leader in cytology innovation. The company conducts in-house research,
development, and production, thus ensuring the highest standards of quality. Hospitex offers the world’s most advanced
Liquid-Based Cytology (LBC) technology, capable of processing any cytological sample with unmatched precision. Hospitex is
uniquely positioned as the only company fully prepared for seamless digital integration, paving the way for a transformative
future in cytology diagnostics.

For more information, visit: www.hospitex.com



Contacts

Ikonisys NewCap NewCap
Alessandro Mauri Louis-Victor Delouvrier/Thomas Cozzolino Nicolas Mérigeau
CFO Investor Relations Media Relations
investors@ikonisys.com Ikonisys@newcap.eu Ikonisys@newcap.eu
Tel. : +33 (0)1 44 71 94 94 Tel. : +33 (0)1 44 71 94 98



Disclaimer

This press release contains forward-looking statements about the Company’s prospects and development. These statements
are sometimes identified by the use of the future tense, the conditional tense and forward-looking words such as “believe”,
“aim to”, “expect”, “intend”, “estimate”, “believe”, “should”, “could”, “would” or “will” or, where appropriate, the negative
of these terms or any other similar variants or expressions. This information is not historical data and should not be construed
as a guarantee that the facts and data set forth will occur. This information is based on data, assumptions and estimates
considered reasonable by the Company. It is subject to change or modification due to uncertainties relating to the economic,
financial, competitive and regulatory environment. This information contains data relating to the Company’s intentions,
estimates and objectives concerning, in particular, the market, strategy, growth, results, financial situation and cash flow of
the Company. The forward-looking information contained in this press release is made only as of the date of this press
release. The Company does not undertake to update any forward-looking information contained in this press release, except
as required by applicable law or regulation. The Company operates in a competitive and rapidly changing environment and
therefore cannot anticipate all of the risks, uncertainties or other factors that may affect its business, their potential impact
on its business or the extent to which the materialization of any one risk or combination of risks could cause results to differ
materially from those expressed in any forward-looking information, it being recalled that none of this forward-looking
information constitutes a guarantee of actual results.




3/3